Blog icon

It can be a logistical challenge to transport vaccines that require cold storage to remote areas. ©  Stephen Bugno 2014

Most of the COVID-19 vaccines currently being distributed require some form of cold storage. Both Pfizer and Moderna need to be kept at temperatures well below zero while AstraZeneca can be stored in standard refrigerated conditions, around 4 degrees Celsius.

Transporting these products relies on a supply chain of freezers and temperature-controlled shipping methods called the "cold chain".

The challenge is that in remote or resource-constrained areas of the world, there can be logistical issues that mean there are no reliable methods to keep vaccines at low temperatures.

Temperature-stable vaccines

Researchers around the world are addressing this need and racing to develop 'warm' vaccines for COVID-19, that can remain stable without any refrigeration.

Scientists at the Indian Institute of Science and Mynvax have developed a heat tolerant vaccine, which has undergone pre-clinical trials.

Results from pre-clinical vaccine trials in India, published in a peer-reviewed paper, have shown that Mynvax formulations triggered a strong immune response in mice and protected hamsters from the coronavirus, and remained stable at 37°C up to a month and at 100°C for up to 90 minutes.

Evaluation of Mynvax exposed to live SARS-CoV-2 virus

A scientist working under high-containment at CSIRO’s Australian Centre for Disease Preparedness in Geelong, Victoria.

A team of scientists at ACDP led a study investigating the effectiveness of antibodies in sera (blood samples) from the vaccinated mice to neutralise the virus.

He exposed the sera to live virus of all current SARS-CoV-2 variants of concern.

Our results

Results of the study have shown that all samples studied were capable of consistent and effective neutralisation of the Alpha, Beta, Gamma and Delta SARS-CoV-2 variants.

Results from this study will support selection of the most suitable candidate for planned human clinical trials in India, in late 2021.

The peer-reviewed paper, Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative, was published by ACS Infectious Diseases on 15 July 2021.

Contact us

Find out how we can help you and your business. Get in touch using the form below and our experts will get in contact soon!

CSIRO will handle your personal information in accordance with the Privacy Act 1988 (Cth) and our Privacy Policy.

First name must be filled in

Surname must be filled in

I am representing *

Please choose an option

Please provide a subject for the enquriy

0 / 100

We'll need to know what you want to contact us about so we can give you an answer

0 / 1900

You shouldn't be able to see this field. Please try again and leave the field blank.